Profile data is unavailable for this security.
About the company
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
- Revenue in USD (TTM)22.06m
- Net income in USD-30.97m
- Incorporated2023
- Employees176.00
- LocationCASI Pharmaceuticals Inc1701-1702, China Central Office Tower 1,BEIJING 100025ChinaCHN
- Phone+86 1 065618789
- Websitehttp://www.casipharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Odonate Inc | 0.00 | -102.07m | 49.87m | 137.00 | -- | 1,839.01 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| BGM Group Ltd | 29.87m | -7.86m | 50.59m | 298.00 | -- | 1.15 | -- | 1.69 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Aadi Bioscience Inc | 25.07m | -61.69m | 56.20m | 53.00 | -- | 0.8149 | -- | 2.24 | -2.29 | -2.29 | 0.9285 | 2.80 | 0.2225 | 0.696 | 4.09 | 281,685.40 | -54.75 | -50.25 | -65.27 | -56.15 | 87.39 | -- | -246.06 | -473.97 | 4.54 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| bluebird bio Inc | 53.12m | -300.52m | 57.77m | 375.00 | -- | -- | -- | 1.09 | -1.84 | -1.84 | 0.3039 | -0.0298 | 0.0985 | 2.03 | 4.42 | 141,653.30 | -55.72 | -34.75 | -96.37 | -40.84 | -43.49 | -124.35 | -565.74 | -5,770.41 | 0.3272 | -13.37 | 1.03 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
| OptiNose Inc | 75.67m | -31.15m | 59.56m | 132.00 | -- | -- | -- | 0.787 | -0.2216 | -0.2216 | 0.5416 | -0.2725 | 0.6512 | 0.7659 | 2.96 | 573,272.80 | -26.80 | -48.25 | -- | -98.95 | 90.21 | 86.96 | -41.16 | -131.66 | 0.7198 | -1.61 | 1.48 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Cellectar Biosciences Inc | 0.00 | -49.67m | 64.10m | 20.00 | -- | 41.37 | -- | -- | -1.67 | -1.67 | 0.00 | 0.4079 | 0.00 | -- | -- | 0.00 | -168.84 | -83.69 | -450.38 | -99.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Hongchang International Co Ltd | 5.42m | -208.79k | 66.15m | 8.00 | -- | 1.63 | -- | 12.21 | -0.0004 | -0.0004 | 0.0104 | 0.0784 | 0.0991 | 5.50 | 37.20 | -- | -0.2731 | -7.98 | -0.2965 | -10.94 | 4.51 | 11.47 | -2.76 | -64.88 | 4.64 | -- | 0.3169 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 67.19m | 217.00 | -- | 0.4959 | -- | 21.13 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 22.06m | -30.97m | 70.36m | 176.00 | -- | 5.08 | -- | 3.19 | -2.23 | -2.23 | 1.59 | 1.03 | 0.32 | 0.9265 | 2.03 | 125,312.50 | -43.04 | -34.75 | -66.19 | -46.91 | 54.31 | 55.98 | -134.50 | -153.72 | 2.32 | -- | 0.58 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Rockwell Medical Inc | 98.92m | -1.24m | 71.10m | 237.00 | -- | 2.44 | 49.86 | 0.7188 | -0.0496 | -0.0496 | 3.23 | 0.9015 | 1.80 | 14.45 | 10.84 | 417,371.30 | -2.25 | -46.29 | -3.34 | -65.38 | 16.91 | 4.66 | -1.25 | -36.51 | 2.00 | 0.3194 | 0.2654 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
| Journey Medical Corp | 57.77m | -18.34m | 77.43m | 58.00 | -- | 9.87 | -- | 1.34 | -0.9276 | -0.9276 | 2.93 | 0.5271 | 0.889 | 2.16 | 6.19 | 996,051.80 | -28.22 | -- | -76.21 | -- | 57.32 | -- | -31.74 | -- | 1.03 | -13.65 | 0.6582 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| I-Mab ADR | -100.00bn | -100.00bn | 77.57m | 220.00 | -- | 0.33 | -- | -- | -- | -- | -- | 2.91 | -- | -- | -- | -- | -- | -35.51 | -- | -41.43 | -- | -- | -- | -509.54 | -- | -- | 0.00 | -- | 111.86 | -13.65 | 44.45 | -- | -5.95 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.37m | 35.00 | 391.37 | 348.44 | -- | 35.44 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to CASI Pharmaceuticals Inc's reporting currency: US Dollar USD
2.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Shields Capital Management LLCas of 30 Sep 2024 | 89.22k | 0.67% |
| Adar1 Capital Management LLCas of 30 Sep 2024 | 64.84k | 0.48% |
| Wellington Shields & Co. LLC (Investment Management)as of 30 Sep 2024 | 43.09k | 0.32% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 41.50k | 0.31% |
| Woodline Partners LPas of 30 Sep 2024 | 30.53k | 0.23% |
| Citadel Advisors LLCas of 30 Sep 2024 | 22.71k | 0.17% |
| Geode Capital Management LLCas of 30 Sep 2024 | 19.36k | 0.14% |
| UBS Securities LLCas of 30 Sep 2024 | 14.68k | 0.11% |
| Brewin Dolphin Wealth Management Ltd.as of 30 Sep 2024 | 6.90k | 0.05% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 1.38k | 0.01% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
